Pretreatment risk factors for endoscopic noncurative resection of gastric cancers with undifferentiated‐type components
Yusuke Horiuchi(Japanese Foundation For Cancer Research), Manabu Muto(Kyoto City Hospital), Noriaki Hasuike(Akebono Clinic), Hiroto Miwa(Toyo Institute of Food Technology), Masanori Terashima(Shizuoka Cancer Center), Tomonori Yano(National Cancer Centre Japan), Junki Mizusawa(Japan Clinical Cancer Research Organization), Toshiyuki Yoshio(Japanese Foundation For Cancer Research), Kohei Takizawa(Shizuoka Cancer Center), Narikazu Boku(Tokyo Medical University), Hiroyuki Ono(Shizuoka Cancer Center), Naohiro Yoshida(Ishikawa Prefectural Central Hospital)
Cited by 5
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
|International Journal of Clinical Oncology|2015|600
Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer
|Digestive Endoscopy|2015|575